CD79b

CD79b

a type I transmembrane protein on B cells that mediates signal transduction; expressed in B-cell tumors and B-cell acute leukoblastic leukemias.
References in periodicals archive ?
Transcription analysis of 44 CD genes was also carried out, indicating 24 CD genes (CD3E, CD244, CD69, CD247, CD40L, CD38, CD5L, CD44, CD5, CD83, CD163L1, CD36, CD14, CD28, CD200R1A, CD40, CD59, CD200, CD4, CD2, CD72, CD180, CD79B, and CD93) to be markedly increased by 2.
The other clone was positive for CD10 (in cases with FL or DLBCL) or negative for CD5 and had strong surface expression of CD20, CD79b, and FMC7 (in MZL).
Flow cytometry is essential for determining the clonality of B-lymphocytes and the following characteristic CLL-cell-surface phenotypes: the presence of CD 19, CD5, CD23 and CD43, weak expression of CD20 and CD79b, and kappa or lambda immunoglobulin light chains (8), (9).
Protein targeting CD32B and CD79B for autoimmune diseases
This product candidate incorporates MacroGenics proprietary platform for Dual-Affinity Re-Targeting (DART) to simultaneously engage CD32B and CD79B, which are two B-cell surface proteins.
In the part of up and different stages of immune responses in both chicken down regulated genes differentially expressed, TLR5, groups, while CCL1, IL8, CD79B and CCL5 were THBS1, KIT, and FGF10 were identified to be up-regulated identified to be down-regulated, and are shown in Table 2 and 3.
B-Cell Prolymphocytic Leukemia: sIgM, sIgD+/-, pan B+ (CD19, CD20, CD22, CD79a, CD79b, and FMC-7), [CD5.
Diagnosis CD5 CD10 CD19 CD20 CD23 SLL/CLL (a) + - + +(w) + Mantle cell lymphoma + - + + - Follicle center lymphoma - + + + -/+ Marginal zone lymphoma - - + + - Hairy cell leukemia - - + + - Diagnosis CD79b FMC-7 CD25 CD11C CD103 SLL/CLL (a) - - -/+ +/_ - Mantle cell lymphoma + + - - - Follicle center lymphoma +/- +/- - - - Marginal zone lymphoma +/- +/- -/+ + - Hairy cell leukemia +/- +/- +/- + + (a) SLL/CLL, small lymphocytic lymphoma/chronic lymphocytic leukemia; +, positive; -, negative; +/-, often positive; -/+, occasionally positive; w, weak expression.
A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (Abstract #56)
In addition, NeoGenomics launched a lymphoma profiling test specifically to predict susceptibility to BTK inhibitors and test for mutations in CXCR4, CD79B, MYD88, and CARD11 genes in various types of lymphoma.
CD79b expression in chronic lymphocytic leukemia: association with trisomy 12 and atypical immunophenotype.
Within the ABC subtype group, only patients who had a CD79B mutation responded to treatment; patients with only an MYD88 mutation did not respond to treatment, suggesting a MYD88-dependent but BCR-independent pathogenesis for some DLBCL tumors.